The treatment of morning hypertension has not been established. We compared the efficacy and safety of a losartan/hydrochlorothiazide (HCTZ) combination and high-dose losartan in patients with morning hypertension. A prospective, randomized, open-labeled, parallel-group, multicenter trial enrolled 216 treated outpatients with morning hypertension evaluated by home blood pressure (BP) self-measurement. Patients were randomly assigned to receive a combination therapy of 50 mg losartan and 12.5 mg HCTZ (n=109) or a high-dose therapy with 100 mg losartan (n=107), each of which were administered once every morning. Primary efficacy end points were morning systolic BP (SBP) level and target BP achievement rate after 3 months of treatment. At baseline, BP levels were similar between the two therapy groups. Morning SBP was reduced from 150.3±10.1 to 131.5±11.5 mm Hg by combination therapy (P<0.001) and from 151.0±9.3 to 142.5±13.6 mm Hg by high-dose therapy (P<0.001). The morning SBP reduction was greater in the combination therapy group than in the high-dose therapy group (P<0.001). Combination therapy decreased evening SBP from 141.6±13.3 to 125.3±13.1 mm Hg (P<0.001), and high-dose therapy decreased evening SBP from 138.9±9.9 to 131.4±13.2 mm Hg (P<0.01). Although both therapies improved target BP achievement rates in the morning and evening (P<0.001 for both), combination therapy increased the achievement rates more than high-dose therapy (P<0.001 and P<0.05, respectively). In clinic measurements, combination therapy was superior to high-dose therapy in reducing SBP and improving the achievement rate (P<0.001 and P<0.01, respectively). Combination therapy decreased urine albumin excretion (P<0.05) whereas high-dose therapy reduced serum uric acid. Both therapies indicated strong adherence and few adverse effects (P<0.001). In conclusion, losartan/HCTZ combination therapy was more effective for controlling morning hypertension and reducing urine albumin than high-dose losartan.
Cardiovascular events, such as stroke and myocardial infarction, occur most frequently in the morning.1, 2 Elevation of blood pressure (BP) in the early morning (morning hypertension) is a risk factor for cardiovascular events in the morning.3, 4, 5, 6 A recent study using home-based BP self-measurement revealed that morning hypertension exists in ∼65% of patients receiving antihypertensive medications.7 Currently, the treatment of morning hypertension has not been established.
Current guidelines for the management of hypertension recommend a combination therapy of antihypertensive agents when an antihypertensive monotherapy cannot achieve target BP levels.8, 9 Among various combinations, an angiotensin II type-1 receptor blocker (ARB) combined with a small dose of thiazide diuretic is desirable because the two drugs have complementary mechanisms of action, effectively reduce BP, and are generally well tolerated.10, 11 A high-dose regimen of ARB is another treatment option. At present, however, little or no information is available on the efficacy of the ARB/thiazide diuretic combination for controlling morning hypertension.
Therefore, we conducted a prospective, randomized, open-labeled, multicenter trial to determine the efficacy and safety of a fixed-dose combination of losartan and hydrochlorothiazide (HCTZ) and a high dose of losartan in the treatment of patients with morning hypertension. For this purpose, outpatients experiencing morning hypertension despite antihypertensive medications were randomly assigned to receive a ‘combination therapy’ with a combination of 50 mg losartan and 12.5 mg HCTZ or a ‘high-dose therapy’ with 100 mg losartan. The primary efficacy end points were morning systolic BP (SBP) level and target BP achievement rate after 3 months of treatment on the basis of home BP self-measurement.
The design of this study was a 3-month prospective, randomized, open-labeled, parallel-group, multicenter trial, with a blinded end-point assessment. This study was performed by the Morning Hypertension and Angiotensin Receptor Blocker/Hydrochlorothiazide Combination Therapy Study investigators in Japan (listed in Supplementary Data). The Institutional Review Boards or Ethics Committees of all participating institutions approved the study protocol. All patients provided written informed consent.
Outpatients who had morning hypertension despite antihypertensive medications were enrolled in the study. Morning hypertension was defined as a morning SBP⩾135 mm Hg, diastolic BP (DBP)⩾85 mm Hg or both9 on 7 different days of home BP self-measurements during the run-in period (at least 1 month). Exclusion criteria included secondary hypertension, malignant hypertension or uncontrolled hypertension (for example, DBP⩾120 mm Hg), uncontrolled diabetes mellitus with HbA1c ⩾9.0%, a history of gout or serum uric acid ⩾8.0 mg dl−1, serum creatinine ⩾2.0 mg dl−1, serum potassium ⩾5.5 mmol l−1, liver damage (for example, alanine aminotransferase or γ-GTP level >3 × the upper normal limit), administration of a thiazide diuretic, administration of an ARB or angiotensin-converting enzyme inhibitor (ACEI) exceeding the standard doses approved in Japan, and the presence of contraindications for thiazides or ARBs.
Patients were randomly assigned to receive a combination of 50 mg losartan and 12.5 mg. HCTZ (combination therapy) or 100 mg losartan (high-dose therapy), each of which were administered once every morning. A 50-mg losartan/12.5-mg HCTZ combination tablet was used for the combination therapy. The envelope method was used for randomization. If patients had been administered an ARB or ACEI, the ARB or ACEI was switched to the losartan/HCTZ combination or 100 mg losartan. If an ARB or ACEI had not been prescribed, one of the prescribed antihypertensives was changed to either of the test drugs. There was no washout period before the randomization. The prescription of antihypertensive agents was not changed during the observation period.
On the day of the randomization, the initial evaluation (that is, medical history, medications) and laboratory tests were performed after written informed consent was obtained. Clinic BP values, adherence and information about adverse events were routinely recorded at each hospital visit every 4 weeks. After the 3-month treatment, the follow-up evaluation and laboratory tests were repeated. Adherence was semi-quantitatively evaluated: 1, 80% or more; 2, 50–80%; 3, <50%. The adverse events included intractable high BP (for example, DBP >120 mm Hg), intractable hypotension symptoms (for example, fainting or dizziness), hyperkalemia (potassium >6.0 mmol l−1), laboratory data abnormalities (for example, doubling increase of serum creatinine or transaminases) and any other conditions that the attending physicians considered to be medically necessary to protect the patients’ best interests.
Patients were instructed to perform BP self-measurements at home in the early morning (within 1 h after waking up, after urination, before dosing in the morning, before breakfast and after resting for 1–2 min in a sitting position) and in the evening (before bedtime, after resting for 1–2 min in a sitting position) every day, according to the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2009 (JSH2009 guidelines).9 Cuff oscillometry was applied using electronic upper arm-cuff devices. The type of devices is unknown, but the devices used were certified to comply with the Association for the Advancement of Medical Instrumentation standards. Each patient used the same type of home BP monitoring device throughout the study. The values of the first measurements taken each morning and evening were recorded. The measurements of the last 7 days preceding each clinic visit were averaged for the morning and evening BP values. BP was measured in the clinic using a sphygmomanometer after 5 min resting in a seated position at 1- to 2-min intervals. At least two measurements were averaged for the clinic BP values.9
Circulating biochemical parameters and urinary albumin excretion were measured in the morning in a fasting state at baseline and after 3 months of treatment. All assays were performed using a commercially available laboratory. Estimated glomerular filtration rates (eGFR) were calculated with the Cockcroft-Gault equation.12 Urine albumin levels were determined from a spot urine sample using a turbidimetric immunoassay and expressed as the urine albumin/creatinine ratio (urine albumin/creatinine ratio (UACR), mg g−1 creatinine).13
The primary efficacy end points were morning SBP level and target BP achievement rate in the morning (SBP <135 mm Hg and DBP <85 mm Hg) after the 3-month-treatment period. The secondary efficacy end points included (1) evening SBP level and the achievement rate of evening target BP (SBP <135 mm Hg and DBP <85 mm Hg), (2) clinic SBP level and target BP achievement ratio in the clinic (SBP <140 mm Hg and DBP <90 mm Hg) and (3) changes in serum potassium, uric acid, plasma type-B natriuretic peptide, eGFR and urinary albumin secretion after the 3-month-treatment period. The safety end points were adherence to medications and the prevalence of adverse events during the 3-month-treatment period.
Statistical analysis was performed using commercially available software (IBM SPSS Statistics 18.0J, IBM, Tokyo, Japan). Data are expressed as mean±s.d. Because of skewed distributions, natural logarithmic transformations were performed for triglycerides, B-type natriuretic peptide and UACR before the data analyses. Paired Student's t-test and the χ2 test were applied to determine the significance of differences between baseline and post-treatment values. Unpaired Student's t-test and the χ2 test were used for detecting the significance of differences between the two treatment groups. A repeated measures analysis of variance followed by the Bonferroni/Dunn test was performed to evaluate the differences in the time-dependent changes between the two therapy groups. Differences were considered statistically significant at P<0.05. To detect a 5-mm Hg between-group BP difference with a power of 90% and a minimum significance level of P<0.05, given a s.d. of 10 mm Hg, 86 patients per group were necessary.
Baseline characteristics and demographics
A total of 216 patients were randomly assigned to the combination therapy (n=107) and high-dose therapy (n=109) groups (Table 1). The mean age of participants was 67.8 years (ranging from 37 to 92 years; 50% male). Morning BP was significantly higher than evening BP (P<0.001). At baseline, BP levels and target BP achievement rates were similar between the combination therapy and high-dose therapy groups. The groups had similar characteristics, with the exception of male gender prevalence, low-density lipoprotein cholesterol level and β-blocker use, which were slightly greater in the combination therapy group. During the run-in period, the average number of antihypertensive medications was 1.63±0.81 and 1.57±0.67 per patient in the combination therapy and high-dose therapy groups, respectively (no significance (NS)). An ACEI or ARB was prescribed to 93.6% in combination therapy and 94.4% in high-dose therapy (NS).
Follow-up and safety end points
During the follow-up period, 53.2% of patients in the combination therapy group and 52.3% of patients in the high-dose therapy group had no co-administered antihypertensive drugs (NS; Table 1). The frequency of co-administration of Ca channel blockers, α-blockers, β-blockers, loop diuretics and aldosterone blockers was similar between the two groups.
Six (5.5%) patients receiving combination therapy and five (4.7%) patients receiving high-dose therapy were withdrawn or lost to follow-up, primarily because of these patients relocated (NS; Figure 1). Table 2 illustrates that the adherence to medications was high in both groups throughout the observation period. The follow-up was discontinued because of adverse effects in four (3.7%) patients receiving combination therapy and five (4.7%) patients receiving high-dose therapy (NS). However, no serious adverse effects were reported in either group (Table 2).
As shown in Figure 1, 97 patients receiving combination therapy and 99 receiving high-dose therapy completed the 3-month treatment and were included in the efficacy analyses.
Primary efficacy end points
Combination therapy reduced morning SBP from 150.3±10.1 to 131.5±11.5 mm Hg (P<0.001), and high-dose therapy reduced morning SBP from 151.0±9.3 to 142.5±13.6 mm Hg (P<0.001) after 3 months of treatment (Figure 2a). Post-treatment morning SBP levels were lower in the combination therapy group than in the high-dose therapy group (P<0.001). Combination therapy increased the target achievement rate of morning BP to 58.7%, and high-dose therapy increased it to 27.0% (Figure 3). Combination therapy indicated a twofold greater target BP achievement rate for morning BP than high-dose therapy (P<0.001).
Secondary efficacy end points
Evening SBP was reduced from 141.6±13.3 to 125.3±13.1 mm Hg by combination therapy (P<0.001) and from 138.9±9.9 to 131.4±13.2 mm Hg by high-dose therapy (P<0.01; Figure 2b). Although the achieved SBP levels were similar between the two groups, combination therapy induced a greater evening SBP reduction than high-dose therapy (P<0.001). The target BP achievement rate of evening BP was improved from 24.2 to 79.0% by combination therapy and from 28.3 to 61.7% by high-dose therapy (P<0.001 for both; Figure 3). After treatment, the target BP achievement rate of evening BP was greater in the combination therapy group than in the high-dose therapy group (P<0.05).
Combination therapy reduced clinic SBP from 147.0±14.3 to 128.6±14.7 mm Hg (P<0.001), and high-dose therapy reduced clinic SBP from 147.5±13.8 to 140.0±15.2 mm Hg (P<0.05; Figure 2c). Post-treatment clinic SBP levels were lower from combination therapy than from high-dose therapy (P<0.001). Target BP achievement rates in the clinic were increased from 25.6 to 75.6% by combination therapy and from 22.8 to 51.3% by high-dose therapy (P<0.001 for both; Figure 3). Combination therapy improved the post-treatment target achievement rates of clinic BP more than high-dose therapy (P<0.01).
Changes in UACR, uric acid, eGFR and HbA1c
UACR was reduced by combination therapy (P<0.05) but was not changed by high-dose therapy after the 3-month-treatment period (Figure 4a). The serum uric acid levels were decreased by high-dose therapy (P<0.001), but it was not changed by combination therapy (Figure 4b). There were no differences in eGFR and HbA1c levels between combination therapy and high-dose therapy groups after the 3-month-treatment period (Figures 4c and d). Neither therapy affected other biochemical parameters, such as serum potassium and B-type natriuretic peptide, after the 3-month-treatment period (Supplementary Table).
This study indicated that among patients with morning hypertension undergoing treatment, combination therapy with 50 mg losartan and 12.5 mg HCTZ and high-dose therapy with 100 mg losartan decreased SBP levels and improved target BP achievement rates. Combination therapy reduced morning and clinic SBP more than high-dose therapy, and the improvement of target BP achievement rates in the morning, evening and the clinic were greater with combination therapy than with high-dose therapy. Combination therapy reduced urine albumin excretion whereas high-dose therapy reduced serum uric acid levels. Both therapies were safe and well tolerated. This study provides the first evidence for the efficacy and safety of losartan/HCTZ combination therapy for patients with uncontrolled morning hypertension on the basis of home BP self-measurements.
Home-based BP measurements have been indicated to be superior to office BP measurements in the prediction of hypertensive organ damage and prognosis.14, 15, 16, 17 Self-measurement of home BP is now popular in clinical practice for hypertension treatment in Japan.18, 19 A recent study has confirmed that morning BP taken by BP self-measurements at home is similar to that by 24-h ambulatory BP monitoring.20 Thus, the recent Japanese guidelines appreciate its use in the diagnosis and management of hypertension.9 In middle-aged and elderly populations, SBP is more closely associated with cardiovascular prognosis than DBP.21, 22 Of the patients participating in this study, the mean age was 67.8 years, and 98% were >45 years. We therefore primarily evaluated SBP levels. More than 90% of the enrolled patients had been administered an ARB before this study was initiated. Thus, the current observations mostly reflect the switching effects from a standard dose of ARB to the combination therapy with losartan and HCTZ or to a high dose of losartan.
Although combination therapy and high-dose therapy reduced morning SBP and improved the target BP achievement rate, combination therapy was superior in controlling morning hypertension through a greater SBP reduction and a greater improvement of target BP achievement rates (Figures 2 and 3). The superiority of combination therapy to high-dose therapy was also documented for the evening and clinic BP measurements. There are several possible reasons for the superiority of combination therapy. First, the combination of ARB and thiazide diuretic exerts a synergistic BP-lowering effect through complementary mechanisms of action whereas the antihypertensive effect of ARBs is not dose dependent.10, 11, 23 Second, 50 mg of losartan combined with 12.5 mg of HCTZ has a longer duration and a greater trough-to-peak ratio of BP-lowering effect than once daily 100 mg losartan.24 Next, increased salt sensitivity is associated with a non-dipper pattern of circadian BP rhythm.25, 26 A non-dipper pattern contributes to morning hypertension in some patients.27, 28, 29 Thiazide diuretics have been indicated to not only improve salt sensitivity but also shift the circadian BP rhythm from non-dipper to dipper in hypertensive patients.25, 30 Thus, combination therapy has an advantage over high-dose therapy for controlling morning hypertension.
The urinary albumin secretion is an established prognostic risk factor for cardiovascular and renal outcomes.31, 32, 33 Long-term trials have indicated an antiproteinuric effect of losartan.33, 34, 35, 36 In this study, the 3-month treatment with 100 mg losartan failed to show a significant UACR reduction in patients with morning hypertension (Figure 4a). This negative result may be explained by the fact that most patients had already been administered a standard dose of ARB or ACEI before the randomization. In contrast, UACR was significantly reduced by combination therapy (Figure 4a). The use of diuretics may have affected the UACR reduction by reducing the GFR. However, eGFR was not changed by the 3-month treatment with combination therapy (Figure 4c). Thus, the UACR reduction may be attributable to a greater BP-lowering effect by combination therapy.
Serum uric acid elevation is one of the clinical concerns regarding the use of thiazide diuretics because diuretic-induced elevation of uric acid to >1.0 mg dl−1 may be a risk factor for coronary events independent from achieved BP control.37 Note that a high dose of losartan brought a further uric acid reduction in the patients studied, most of whom had received a standard dose of ARB during the run-in period (Figure 4b). This finding supports the notion that losartan is a unique ARB, which reduces serum uric acid levels through the cis-inhibitory effects on the reabsorption of uric acid by the renal uric acid transporter 1.38 In this study, combination therapy did not increase uric acid levels (Figure 4b), suggesting that losartan minimized the HCTZ-induced uric acid elevation in combination therapy. This beneficial effect is a characteristic feature distinguishing losartan from other ARBs.39
In this study, adherence was substantially high in both therapy groups throughout the observation period (Table 2), which is in line with previous studies demonstrating that losartan and a combination of losartan and a small dose of HCTZ were well tolerated in hypertensive patients.40, 41, 42 In addition, BP self-measurements at home might be useful in raising the adherence to hypertensive medications by improving patient motivation.43
Combination therapy included more male subjects than high-dose therapy (Table 1). Thus, the imbalance of gender may have affected the results of this study. However, as shown in the Supplementary Figure, there were no gender differences in the effects of combination therapy or high-dose therapy on the primary end points (morning SBP levels and target BP achievement rates after the 3-month-treatment period).
From this study, it remains unknown whether combination therapy would provide a greater reduction in future cardiovascular events in patients with morning hypertension than high-dose therapy. A large-scale, long-term, randomized trial is necessary to address this issue. Second, adverse effects of diuretics, such as glucose intolerance, are major concerns in the clinical setting. Therefore, a longer observation period is required to examine adverse metabolic effects, such as electrolyte imbalance, glucose intolerance and hyperuricemia. Next, bedtime administration of antihypertensives was reported to improve BP control more than morning administration.44, 45 The feasibility of bedtime administration of combination therapy and high-dose therapy for morning hypertension should be determined in future studies.
In conclusion, combination therapy with a standard dose of losartan and a low dose of HCTZ is more effective for controlling morning hypertension and reducing urine albumin excretion than high-dose therapy with losartan. These beneficial effects may be attributable to the consistent and well-maintained BP-lowering effects of the combination therapy.
Goldberg RJ, Brady P, Muller JE, Chen ZY, de Groot M, Zonneveld P, Dalen JE . Time of onset of symptoms of acute myocardial infarction. Am J Cardiol 1990; 66: 140–144.
Kelly-Hayes M, Wolf PA, Kase CS, Brand FN, McGuirk JM, D’Agostino RB . Temporal patterns of stroke onset. The Framingham Study. Stroke 1995; 26: 1343–1347.
Muller JE, Tofler GH, Stone PH . Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733–743.
Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K . Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–1406.
Asayama K, Ohkubo T, Kikuya M, Obara T, Metoki H, Inoue R, Hara A, Hirose T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y . Prediction of stroke by home ‘morning’ versus ‘evening’ blood pressure values: the Ohasama study. Hypertension 2006; 48: 737–743.
Metoki H, Ohkubo T, Imai Y . Diurnal variations in blood pressure: clinical implications and pathogenesis. Hypertens Res 2010; 33: 652–656.
Obara T, Ito K, Ohkubo T, Shibamiya T, Shinki T, Nakashita M, Hara A, Metoki H, Inoue R, Asayama K, Kikuya M, Mano N, Imai Y . Uncontrolled hypertension based on morning and evening home blood pressure measurements from the J-HOME study. Hypertens Res 2009; 32: 1072–1078.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B . Management of arterial hypertension of the European Society of Hypertension; European Society of Cardiology 2007 Guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187.
Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H . The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 3–107.
MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS . Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278–285.
Yamada Y, Tsuboi K, Hattori T, Murase T, Ohtake M, Furukawa M, Ueyama J, Nishiyama A, Murohara T, Nagata K . Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension. Hypertens Res 2011; 34: 809–816.
Cockcroft DW, Gault MH . Prediction of creatinine clearance from serum creatinine. Nephron 1975; 13: 31–41.
Ewald B, Attia J . Which test to detect microalbuminuria in diabetic patients? A systematic review. Aust Fam Physician 2004; 33: 565–567.
Tsuji I, Imai Y, Nagai K, Ohkubo T, Watanabe N, Minami N, Itoh O, Bando T, Sakuma M, Fukao A, Satoh H, Hisamichi S, Abe K . Proposal of reference values for home blood pressure measurement: prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens 1997; 10: 409–418.
Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Kikuya M, Ito S, Satoh H, Hisamichi S . Home blood pressure measurement has a stronger predictive power than does screening blood pressure measurement: a propulation-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971–975.
Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM . Cardiovascular prognosis of ‘masked hypertension’ detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342–1349.
Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G . Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111: 1777–1783.
Obara T, Ohkubo T, Fukunaga H, Kobayashi M, Satoh M, Metoki H, Asayama K, Inoue R, Kikuya M, Mano N, Miyakawa M, Imai Y . Practice and awareness of physicians regarding home blood pressure measurement in Japan. Hypertens Res 2010; 33: 428–434.
Sato A, Watanabe S, Okubo S, Toi T, Doi T, Nakano H, Tada J, Aonuma K . The therapeutic importance of home blood pressure assessment and combination antihypertensive therapy for achieving target blood pressure control: Ibaraki hypertension assessment trial. Hypertens Res 2010; 33: 1264–1271.
Stergiou GS, Nasothimiou EG . Does dosing antihypertensive drugs at night alter renal or cardiovascular outcome: do we have the evidence? Curr Opin Nephrol Hypertens 2008; 17: 464–469.
Stamler J, Stamler R, Neaton JD . Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153: 598–615.
Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, O’Leary DH, Bryan RN, Anderson M, Lumley T . Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001; 161: 1183–1192.
Fenton C, Keating GM, Scott LJ . Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. Drugs 2003; 63: 2013–2026.
Elliot HL, Meredith PA . Clinical implications of the trough: peak ratio. Blood Press Monit 1996; 1 (Suppl 1): S47–S51.
Uzu T, Kimura G . Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999; 100: 1635–1638.
Kimura G, Dohi Y, Fukuda M . Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovasucular events. Hypertens Res 2010; 33: 515–520.
White WB, Mansoor GA, Tendler BE, Anwar YA . Nocturnal blood pressure epidemiology, determinants, and effects of antihypertensive therapy. Blood Press Monit 1998; 3: 43–51.
Eguchi K, Hoshide S, Kabutoya T, Shimada K, Kario K . Is very low dose hydrochlorothiazide combined with candesartan effective in uncontrolled hypertensive patients? Blood Press Monit 2010; 15: 308–311.
de la Sierra A, Segura J, Gorostidi M, Banegas JR, de la Cruz JJ, Ruilope LM . Diurnal blood pressure variation, risk categories and antihypertensive treatment. Hypertens Res 2010; 33: 767–771.
Burnier M, Brunner HR . Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 1992; 13 (Suppl G): 28–33.
Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D . Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000; 109: 1–8.
Tanihara S, Hayakawa T, Oki I, Nakamura Y, Sakata K, Okayama A, Fujita Y, Ueshima H, NIPPON DATA Research Group. Proteinuria is a prognostic marker for cardiovascular mortality: NIPPON DATA 80, 1980–1999. J Epidemiol 2005; 15: 146–153.
Cerasola G, Cottone S, Mulè G . The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. J Hypertens 2010; 28: 2357–2369.
Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchii Y, Uchida S, Kuwahara M, Yamazaki T . Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—A report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21–30.
de Zeeuw D, Lewis EJ, Remuzzi G, Brenner BM, Cooper ME . Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006; 367: 899–900.
Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D . Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 2007; 25: 871–876.
Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WB . Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–1154.
Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H . Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447–452.
Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I . Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320: 211–217.
Saruta T, Ogihara T, Matsuoka H, Suzuki H, Toki M, Hirayama Y, Nonaka K, Takahashi K . Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res 2007; 30: 729–739.
Shimosawa T, Gohchi K, Yatomi Y, Fujita T . Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs candesartan/amlodipine. Hypertens Res 2007; 30: 831–837.
Naritomi H, Fujita T, Ito S, Ogihara T, Shimada K, Shimamoto K, Tanaka H, Yoshiike N . Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. Hypertens Res 2008; 31: 295–304.
Shimada K, Fujita T, Ito S, Naritomi H, Ogihara T, Shimamoto K, Tanaka H, Yoshiike N . The importance of home blood pressure measurement for preventing stroke and cardiovascular disease in hypertensive patients: a sub-analysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. A prospective nationwide observational study. Hypertens Res 2008; 31: 1903–1911.
Hermida RC, Ayala DE . Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 2009; 54: 40–46.
Parati G, Bilo G . Evening administration of antihypertensive drugs: filling a knowledge gap. J Hypertens 2010; 28: 1390–1392.
We thank Mari Shibata, Naoko Shiotani, Motoko Kakehashi and Midori Ikeda for their secretarial assistance. This study was supported in part by a grant from the Science Frontier Research Promotion Centers from the Ministry of Education, Science, Sports and Culture of Japan.
The authors declare no conflict of interest.
This study was presented in the ‘Late-Breaking Clinical Trials session’ at the 34th Annual Scientific Meeting of the Japanese Society of Hypertension on 20 October 2011.
Supplementary Information accompanies the paper on Hypertension Research website
About this article
Cite this article
Ueda, T., Kai, H., Imaizumi, T. et al. Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension—a prospective, randomized, open-labeled, parallel-group, multicenter trial. Hypertens Res 35, 708–714 (2012). https://doi.org/10.1038/hr.2012.27
- Ang II receptor blockers
- antihypertensive therapy
- clinical trial
- home blood pressure measurement
Revista Colombiana de Cardiología (2018)
Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients
Clinical and Experimental Hypertension (2018)
Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension
The Journal of Clinical Hypertension (2017)
Benefit of losartan/hydrochlorothiazide-fixed dose combination treatment for isolated morning hypertension: The MAPPY study
Clinical and Experimental Hypertension (2015)
Regression of Electrocardiographic Signs of Left Ventricular Hypertrophy by Combined Treatment With Thiazide Diuretic and Angiotensin-II Receptor Blocker
Circulation Journal (2014)